内源性大麻系统与精神分裂症  

Endocannabinoid system and schizophrenia

作　　者：张伟[1] 武海英[1] 胡永杰[1] 李行舟[2] 

机构地区：[1]空军大连航空医学鉴定训练中心,大连116013 [2]军事医学科学院,北京100850

出　　处：《生命科学》2013年第4期347-351,共5页Chinese Bulletin of Life Sciences

摘　　要：内源性大麻系统由大麻受体、内源性大麻素和内源性大麻素的降解酶构成。现已公认的大麻受体包括大麻1型(cannabinoid receptor subtype 1,CB1)受体和大麻2型(cannabinoid receptor subtype 2,CB2)受体,它们广泛分布于中枢和外周神经系统,在认知、情感、动机、痛觉、内分泌、免疫等很多方面发挥重要作用。近几年的一些研究表明,精神分裂症与内源性大麻系统功能失调,尤其是CB1受体的过度激活密切相关。因此,大麻受体可能成为治疗精神分裂症的新靶点。已经对几种CB1受体拮抗剂的抗精神分裂症效果进行了动物实验和临床研究,并取得了一些进展。将对近几年关于内源性大麻系统与精神分裂症的研究进展进行简要综述。The endocannabinoid system is composed of cannabinoid receptor, endocarmabinoids and their degrading enzyme. Till now, two cannabinoid receptors, designated as CB 1 and CB2, have been recognized. They are widely distributed in central nervous system and peripheral system, and play critical roles in many aspects of physiology, including cognition, emotion, motivation, algesia, endocrine, immunity etc. Recent evidence indicated that dysregulation of the endocannabinoid system, especially the overactivity of CB 1 receptor, is involved in the pathogenesis of schizophrenia. Based on this hypothesis, cannabinoid receptor has been taken into account as a new target for schizophrenia. Several researches have indicated CB1 receptor antagonists have antipsychotic properties. In this article, we will briefly review the latest progress in this field.

关 键 词：大麻受体 精神分裂症 拮抗剂 

分 类 号：Q423[生物学—神经生物学] I968[生物学—生理学]